Monoclonal antibody therapy for refractory chronic migraine-like headache related Lyme disease: a case report

Marlon Cantillo-Martínez1,2, Cristian Correa-Arrieta1,2, Fidel Sobrino-Mejía1,3

1Neurology Department, Universidad de La Sabana, Bogotá, Colombia
2Neuromuscular Disease Centre, Instituto Roosevelt, Bogotá, Colombia
3Headache Excelente Center, Unidad de Servicios de Salud Occidente de Kennedy, Bogotá, Colombia

Abstract

Introduction
Lyme disease, caused by Borrelia burgdorferi, can lead to diverse neurological manifestations, including headache. While most Lyme-associated headaches resolve with antibiotics, some may evolve into a refractory chronic migraine-like syndrome. We present a case of post-Lyme chronic migraine-like headache responsive to galcanezumab, a calcitonin gene-related peptide (CGRP) monoclonal antibody.

Case Report
A 42-year-old woman developed chronic migraine-like headaches following treatment for Lyme neuroborreliosis. The headaches were refractory to standard preventive therapies and only partially responsive to onabotulinumtoxinA. Administration of galcanezumab resulted in significant reduction of headache frequency, intensity, and impact on daily activities.

Comment
This case highlights the potential of CGRP-targeted therapies for persistent migraine-like headaches following Lyme neuroborreliosis. The favorable response to galcanezumab suggests a role for CGRP in the pathophysiology of post-Lyme headache. While further research is needed to establish efficacy and safety, clinicians should consider CGRP monoclonal antibodies for chronic migraine-like headaches refractory to standard treatments in the post-infectious phase of Lyme disease. The emergence of chronic migraine-like headaches following Lyme neuroborreliosis and the response to a CGRP monoclonal antibody in this case underscore the importance of considering targeted migraine therapies in the management of persistent headaches after antibiotic treatment. This report contributes to the understanding of Lyme disease sequelae and potential treatment options, warranting further investigation into the utility of CGRP-targeted therapies in this context.

Keywords
Lyme disease
Chronic migraine-like
Colombia
Galcanezumab
Introduction

Lyme disease, a tick-borne infection caused by Borrelia burgdorferi, is transmitted by Ixodes ticks and is more prevalent in temperate northern hemisphere climates (1). Climate change, increased tick reproduction, and human migration are expected to contribute to a significant rise in cases worldwide (2). Lyme disease can affect the central nervous system (neuroborreliosis) in approximately 50% of cases, presenting with various symptoms, including headache (3). Diagnosis involves a two-step serological approach, with an ELISA followed by a confirmatory Western blot (4). Treatment with doxycycline should be initiated in all patients with suspected Lyme disease (4).

While most headaches resolve with antibiotic treatment (5), this case report presents a patient with Lyme borreliosis who developed a refractory chronic migraine-like headache that responded favorably to galcanezumab, a monoclonal antibody targeting calcitonin gene-related peptide (CGRP).

Case Report

A 42-year-old woman from Bogotá, Colombia, presented in May 2022 with a progressive, intermittent, facially distributed exanthema, accompanied by migraine-like headaches occurring 20 times per month, joint pain, cutaneous allodynia, and paresthesias in the trigeminal nerve branches and scalp. She had traveled to Willowsford, Virginia, in October 2021. Physical examination revealed erythematous, round, well-demarcated, non-tender papules on the face, arms, and thighs (Figure 1). Brain MRI demonstrated hyperintensities on T2 and FLAIR images, with diffusion restriction and contrast enhancement in the bilateral frontal and left parietal white matter. Serological testing for B. burgdorferi was positive for IgM and IgG antibodies. Treatment with doxycycline and ceftriaxone resolved most symptoms, but the patient continued to experience chronic migraine-like headaches. Despite treatment with valproic acid, topiramate, propranolol, flunarizine, and onabotulinum toxin type A, the headaches persisted. Galcanezumab treatment significantly reduced headache frequency and intensity and improved daily activities and headache impact (Figure 2).

Figure 1. Clinical presentation of skin lesions in a patient with Lyme disease. Physical examination revealed multiple erythematous, round to oval-shaped, well-demarcated papules on the skin of the thighs. The lesions were non-tender upon palpation. This cutaneous eruption, while not classic for erythema migrans, can be seen in some cases of disseminated Lyme disease.
Monoclonal antibody therapy for refractory chronic migraine – like headache related Lyme disease: a case report

Figure 2. Changes in headache days per month, headache intensity and patient’s HIT-6. HIT-6: Headache Impact Test-6; VAS: visual analogue scale.

Discussion

Lyme disease, primarily transmitted during summer and autumn (2), can manifest with diverse symptoms, including headache, which is common in neuroborreliosis (6,7). Headache can occur during active disease and as a residual symptom following antibiotic treatment (8). The clinical features of headache in Lyme disease are varied, often resembling tension-type headache but not fully meeting IHS criteria, and may be associated with systemic symptoms and neurological manifestations (9).

A proposed pathophysiological mechanism is a local inflammatory process disrupting arachnoid villi, leading to an imbalance between CSF absorption and production (10). Although headache associated with Lyme disease often resolves with antibiotic treatment (5), it may evolve into a post-infectious chronic migraine-like syndrome refractory to standard preventive medications. In our case, Lyme disease was confirmed by serological testing, and while ceftriaxone resolved systemic manifestations, the patient developed chronic migraine-like features refractory to oral prophylaxis and only partially responsive to botulinum toxin therapy. These headaches resolved with CGRP monoclonal antibodies. This case underscores the potential benefit of specific migraine-directed treatments, including CGRP monoclonal antibodies, for patients with persistent post-Lyme migraine-like syndrome following appropriate antibiotic therapy.

Acknowledgements

The authors express their gratitude to the patient and her family for their participation in this case report.

References

Monoclonal antibody therapy for refractory chronic migraine-like headache related Lyme disease: a case report

Marlon Cantillo-Martínez
https://orcid.org/0000-0002-8805-5051
Cristian Correa-Arrieta
https://orcid.org/0000-0003-2985-3026
Fidel Sobrino-Mejía
https://orcid.org/0000-0001-8334-6215

Author’s contribution: All authors contributed equally to this work.

Declaration of conflicting interests: The authors declare that there are no potential conflicts of interest with respect to the research, authorship and/or publication of this article.

Funding: None.